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In this poster, we will present the rapid development of a perfusion process with high productivity for late-stage 
manufacturing. The process uses a Chinese Hamster Ovary (CHO) cell line for monoclonal antibody production. 
Prior to the development, the clinical supply was manufactured by a fed-batch process with the same cell line.  
To achieve desired productivity and comparable quality attributes, we developed a repeated batch shake flask 
model to rapidly screen media and process conditions. Shake flasks were inoculated at 10 × 106 cells/mL and 
maintained in a CO2 incubator with medium exchange for every 48 hours, repeated for at least three times. 
Harvested culture samples were purified on an automated high-throughput purification platform for antibody 
quality attributes analysis. We observed that quality attributes such as N-linked glycans were comparable 
between the shake flask model and the perfusion process ran in 3 L bioreactors. Thus, the repeated batch 
shake flask model was used for Design of Experiments (DOE) or single factor experiments evaluating the 
impact of media components and process conditions on cell growth, productivity, and quality attributes.  
The top conditions were confirmed and optimized in 3 L perfusion bioreactors with an alternating tangential flow 
filtration system (ATF-2) for up to 50 days. By varying media and perfusion conditions, we were able to maintain 
steady state cell density at different levels of  45, 70 and 110 x 106 cells/mL with a range of productivity at 0.8 to 
2.5 g/L/day at maximum perfusion rate of 1.5 vvd. The process efficiency and scalability were assessed. 
Perfusion culture conditions, such as perfusion rates and bleed rates, were evaluated for their effect on steady 
state cell density and productivity. Additionally, culture temperature and medium additives were evaluated to 
understand their impact on productivity and protein quality. As a result of these efforts, a high productivity 
perfusion process producing desired antibody was successfully developed.  
 
